ABBV Jan 2025 165.000 call
| Previous close | 3.9500 |
| Open | 3.8500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 165.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.8500 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Zacks4 Large Drug Stocks to Watch as IBD Market Gains Traction
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
- PR Newswire
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively.
Simply Wall St.AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...
